Welcome to our dedicated page for Redhill Biopharm news (Ticker: RDHL), a resource for investors and traders seeking the latest updates and insights on Redhill Biopharm stock.
Company Overview
RedHill Biopharma Ltd (NASDAQ: RDHL) is a specialty biopharmaceutical company dedicated to the development and commercialization of innovative therapies for gastrointestinal, infectious, and oncological diseases. With a focus on late clinical-stage development and patented drug formulations, the company leverages extensive expertise in clinical research, regulatory strategy, and commercial operations to address unmet medical needs.
Core Business and Market Position
RedHill Biopharma excels in advancing therapeutic candidates from concept to market. Its dual approach of improving existing drugs and pioneering new therapeutic candidates has established a robust pipeline. The company’s flagship products include Talicia, a novel treatment for Helicobacter pylori infections, and Aemcolo, targeted for travelers' diarrhea. Alongside these commercially marketed drugs, RedHill is actively advancing a number of clinical-stage programs such as opaganib, a first‐in‐class, orally administered sphingosine kinase-2 selective inhibitor, and several other candidates (RHB-107, RHB-102, RHB-104, RHB-204) aimed at addressing critical indications in oncology, viral infections, radiation protection, and inflammatory diseases.
Research and Development Excellence
Emphasizing rigorous research and robust clinical validation, RedHill’s R&D strategy leverages both internal expertise and strategic collaborations with U.S. government agencies and leading academic institutions. The company’s clinical trials and research programs are designed to meet the rigorous standards expected in the biopharmaceutical industry, enhancing its credibility and establishing its authority in the field. Through its focus on clinical efficacy, safety, and patented drug formulations, RedHill reinforces its commitment to innovative therapies and patient outcomes.
Operational Strengths and Competitive Differentiators
A key strength of RedHill is its experienced management team, which includes seasoned professionals from Israel, the U.S., Canada, and Europe. Their combined expertise in regulatory affairs, commercialization, and transactional experience allows the company to execute cost-efficient strategies while positioning its products favorably in a competitive market. This balanced approach not only strengthens its current market offering but also ensures continuous innovation and resilience in the face of industry challenges.
Investor and Market Relevance
For investors and market analysts, RedHill Biopharma represents a compelling blend of commercial successes and forward-looking clinical development programs. The company’s strategic focus on gastrointestinal and infectious therapies, combined with its robust pipeline and global network of expertise, underscores its value as a differentiated player in the specialty biopharmaceutical sector. Through its comprehensive approach to product development and commercialization, RedHill continues to solidify its position within a competitive and evolving market landscape.
RedHill Biopharma (Nasdaq: RDHL) announced new manufacturing agreements with Cosmo Pharmaceuticals for two products: Movantik® and RHB-204. Movantik is RedHill's top-selling product for treating opioid-induced constipation, which affects millions. RHB-204 is in Phase 3 trials as a treatment for pulmonary nontuberculous mycobacterial disease, with market potential exceeding $500 million. These agreements enhance RedHill's supply capabilities and support ongoing strategic collaboration with Cosmo.
RedHill Biopharma Ltd. (Nasdaq: RDHL) has announced the dosing of its first patient in a U.S. Phase 2/3 study for RHB-107 (upamostat), aimed at treating symptomatic COVID-19 patients who do not require hospitalization. RHB-107, a potent serine protease inhibitor, demonstrated strong antiviral action against SARS-CoV-2 in preclinical studies. The trial includes 310 patients and utilizes innovative telemetry and home-based monitoring for safety and efficacy, intending to provide effective treatment against emerging viral variants.
On February 17, 2021, RedHill Biopharma Ltd. (Nasdaq: RDHL) announced the dosing of the first patient in its U.S. Phase 2/3 study of RHB-107 (upamostat), targeting symptomatic COVID-19 patients who do not require hospitalization. This investigational drug aims to inhibit viral entry by targeting serine proteases. The study will enroll 310 patients and utilizes innovative home monitoring to enhance safety. RedHill also advances its second COVID-19 candidate, opaganib, for hospitalized patients, with promising efficacy data already reported.
On February 9, 2021, RedHill Biopharma (Nasdaq: RDHL) announced its participation in two key virtual conferences: the SVB Leerink 10th Annual Global Healthcare Conference (Feb 22-26) and the BIO CEO & Investor Digital Conference (Feb 16-18). Dror Ben-Asher, CEO, will present on February 25, while Guy Goldberg, Chief Business Officer, will feature a session on-demand starting February 16. The presentations will be available for 30 days on RedHill's website. The company focuses on gastrointestinal and infectious diseases, with several late-stage clinical programs underway.
RedHill Biopharma Ltd. (Nasdaq: RDHL) will present at two upcoming virtual conferences: the SVB Leerink 10th Annual Global Healthcare Conference from February 22-26, 2021, with a presentation by CEO Dror Ben-Asher on February 25, and the BIO CEO & Investor Digital Conference from February 16-18, 2021, featuring Guy Goldberg, Chief Business Officer. Webcasts will be available for 30 days on RedHill's website. The company focuses on gastrointestinal and infectious diseases, highlighting drugs like Movantik, Talicia, and Aemcolo.
RedHill Biopharma (Nasdaq: RDHL) announced a positive recommendation from the independent Data Safety Monitoring Board (DSMB) to continue its global Phase 2/3 study of opaganib for severe COVID-19, based on a pre-scheduled review of efficacy and safety data. Opaganib has shown potential against viral resistance and has demonstrated improvements in reducing oxygen needs in patients. The study will expand to around 460 patients across 30 sites in 7 countries, with top-line data expected in Q2 2021 and potential emergency use applications.
RedHill Biopharma (Nasdaq: RDHL) has partnered with Cosmo Pharmaceuticals to expand manufacturing capacity for opaganib (Yeliva®), targeting increased demand following potential global emergency use authorizations. Opaganib is a novel SK2 inhibitor aimed at treating COVID-19 pneumonia and has demonstrated efficacy against viral strains. An interim analysis of a Phase 2/3 study is imminent, with promising preliminary safety and efficacy data reported from an earlier Phase 2 trial. The drug holds Orphan Drug designation from the FDA for cholangiocarcinoma.
RedHill Biopharma Ltd. (Nasdaq: RDHL) announced the closing of a $25 million underwritten offering of 3,188,776 American Depositary Shares (ADSs) at $7.84 each. The offering was managed by H.C. Wainwright & Co., with a 30-day option for the underwriter to purchase an additional 478,316 ADSs. Proceeds will be utilized for clinical development, commercialization activities, acquisitions, and general corporate purposes. The securities were registered under a prior shelf registration statement with the SEC.
RedHill Biopharma (Nasdaq: RDHL) has expanded its previously announced offering, purchasing 3,188,776 American Depositary Shares (ADSs) at $7.84 each, totaling approximately $25 million in gross proceeds. The closing is anticipated by January 14, 2021, subject to standard conditions. Additionally, the underwriter holds a 30-day option for purchasing up to 478,316 more ADSs. Proceeds will be allocated to clinical development, commercialization, acquisitions, and general corporate purposes, enhancing the company's financial position in the biopharmaceutical sector.
RedHill Biopharma (Nasdaq: RDHL) announced a firm commitment underwriting agreement with H.C. Wainwright & Co. for 1,275,510 American Depositary Shares (ADSs) at $7.84 per ADS, expecting gross proceeds of approximately $10 million. The offering is projected to close around January 14, 2021, subject to customary conditions. Additionally, the underwriter holds a 30-day option for 191,326 additional ADSs. Proceeds will be allocated to clinical development, commercialization activities, and general corporate purposes.